Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ARX788,Capecitabine,Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $75.0 million
Deal Type : Public Offering
Ambrx Announces Closing of $75 Million Market Priced Registered Offering
Details : The Company intends to use the net proceeds to fund the research and development of its product candidates, including ARX788, a next-generation, site-specific anti-HER2 ADC, being developed for the treatment of HER2-positive metastatic breast cancer.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
June 28, 2023
Lead Product(s) : ARX788,Capecitabine,Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $75.0 million
Deal Type : Public Offering
Lead Product(s) : ARX788,Capecitabine,Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARX788, an anti-HER2 antibody drug conjugate currently being studied broadly in breast cancer, gastric/GEJ cancer and other solid tumor clinical trials.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : ARX788,Capecitabine,Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Eoc Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2017
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Eoc Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2014
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Clinical Research Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2014
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Clinical Research Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 03, 2014
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2014
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : OnkoDataMed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2013
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : OnkoDataMed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 31, 2013
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2012
Lead Product(s) : Lapatinib Ditosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable